Advanz Pharma Corp. Limited completes the acquisition of Intercept Pharmaceuticals, Inc.

On July 1, 2022, ADVANZ PHARMA Corp. Limited ("Advanz Pharma"), a UK-headquartered pharmaceutical company with a strategic focus on speciality and hospital pharmaceuticals in Europe, announced the acquisition of the majority of Intercept Pharmaceuticals, Inc. subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S.

Advanz Pharma will build on this transaction by continuing to strengthen its platform for future acquisitions and in-licensing agreements to drive growth, especially in the areas of gastroenterology and hepatology as well as more broadly in rare diseases.

Fasken advised Advanz Pharma in connection with this transaction with a team led by John Sabetti and including Rachel Charney, Josh Hersh and Krysten Zator (Mergers & Acquisitions); Allyson Marta and Anthony Panacci (Labour, Employment & Human Rights); Mitchell Thaw (Tax); Harry Bhandal (Real Estate); and Mark Vanderveken (Life Sciences).